Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
The FDA has approved UCB Pharma’s investigational agent zilucoplan, a complement C5 inhibitor, to treat patients with myasthenia gravis (MG). Approved under the market name Zilbrysq, the ...
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...
Patients who are taking complement inhibitors may still experience breakthrough hemolysis associated with respiratory viral infections. Patients with PNH should be closely monitored for signs of ...
(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback